(NASDAQ: ZYME) Zymeworks's forecast annual revenue growth rate of 79.07% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.82%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.54%.
Zymeworks's revenue in 2026 is $37,127,000.On average, 14 Wall Street analysts forecast ZYME's revenue for 2026 to be $22,847,456,417, with the lowest ZYME revenue forecast at $19,095,841,346, and the highest ZYME revenue forecast at $29,210,371,558. On average, 14 Wall Street analysts forecast ZYME's revenue for 2027 to be $20,079,336,426, with the lowest ZYME revenue forecast at $9,109,747,360, and the highest ZYME revenue forecast at $29,974,602,583.
In 2028, ZYME is forecast to generate $14,516,131,931 in revenue, with the lowest revenue forecast at $8,414,346,798 and the highest revenue forecast at $22,523,882,278.